KBY Biotech Indexv0.0.34
Search
← Pipeline|Zanutapinarof

Zanutapinarof

Approved
CNT-2570
By Connect Biopharma
Source: Trial-derived·Trials: 1
Modality
ERT
MOA
RAS(ON)i
Target
HER2
Pathway
Sphingolipid
MesoCervical CaRA
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
~Jul 2017
→ ~Oct 2018
NDA/BLA
~Jan 2019
→ ~Apr 2020
Approved
Jul 2020
ApprovedCurrent
NCT05642214
520 pts·Meso
2020-07→TBD·Not yet recruiting
520 total pts1 indication
CompletedCurrentUpcoming
Trial Timeline
Q3
Approved
Not yet…
Not yet recruiting|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT05642214ApprovedMesoNot yet recr...520LiverFat
Competitors (10)
DrugCompanyPhaseTargetMOA
MRK-6781Merck & CoApprovedTIGITRAS(ON)i
GozesotorasibBristol-Myers SquibbNDA/BLAHER2IL-13i
SNY-9073SanofiPhase 2B7-H3RAS(ON)i
VRT-4938Vertex PharmaPreclinicalHER2CDK4/6i
TixarelsinVertex PharmaPhase 1ALKRAS(ON)i
FixatuximabLegend BiotechPreclinicalCFTRRAS(ON)i
ION-1378IonisNDA/BLATROP-2RAS(ON)i
180-3597Innovent BioPreclinicalSHP2RAS(ON)i
ROI-9675Roivant SciencesNDA/BLAHER2USP1i
CGO-2579CG OncologyApprovedTIGITRAS(ON)i